Tags : ESC-Derived


Sangamo Signs an Exclusive License Agreement with Mogrify for iPSC

Shots: Shots: Mogrify to receive upfront, development, regulatory and commercial milestones and will be responsible for the discovery & optimization of the cell conversion technology from iPSCs or ESCs to regulatory T cells Sangamo to get exclusive rights to use Mogrify’s technology to develop Tregs from iPSCs/ESCs. The company anticipates utilizing its ZFP technology & […]Read More